Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arecor Therapeutics PLC ( (GB:AREC) ) just unveiled an announcement.
Arecor Therapeutics has strengthened its intellectual property (IP) portfolio with new patents for its lead product, AT278, and its oral peptide delivery technology. The US and European patents for AT278, an ultra-concentrated and ultra-rapid acting insulin, enhance its potential for integration with automated insulin delivery systems. Additionally, a new patent application for improving oral bioavailability of peptides has been filed, addressing a significant barrier in developing oral peptide therapies. These advancements reinforce Arecor’s position in the biopharmaceutical industry, particularly in the diabetes and cardiometabolic disease sectors, and demonstrate its commitment to innovation and IP protection.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £70.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics PLC’s overall stock score is primarily influenced by its financial performance and valuation challenges. The company is in a growth phase with increasing revenues but faces significant operational and cash flow challenges typical of early-stage biotech firms. Technical analysis indicates short-term bearish momentum, although there is some longer-term support. The negative P/E ratio and lack of dividend yield reflect ongoing profitability struggles and reinvestment in growth.
To see Spark’s full report on GB:AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a clinical stage biopharmaceutical company based in Cambridge, UK, specializing in drug development and delivery for diabetes and other cardiometabolic diseases. The company utilizes its proprietary Arestat® technology platform to develop a portfolio of proprietary products and collaborates with leading pharmaceutical and biotechnology companies. Its flagship product is AT278, an ultra-concentrated, ultra-rapid acting insulin, and it is also advancing a novel oral delivery platform for peptides targeting the obesity and diabetes markets.
Average Trading Volume: 55,612
Technical Sentiment Signal: Hold
Current Market Cap: £27M
Find detailed analytics on AREC stock on TipRanks’ Stock Analysis page.